These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 22529401)

  • 1. Effect of Misalignment between Hospital and Provincial Formularies on Medication Discrepancies at Discharge: PPITS (Proton Pump Inhibitor Therapeutic Substitution) Study.
    Chua D; Chu E; Lo A; Lo M; Pataky F; Tang L; Bains A
    Can J Hosp Pharm; 2012 Mar; 65(2):98-102. PubMed ID: 22529401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proton-pump inhibitor utilization associated with the change to nonpreferred formulary status for esomeprazole in the TRICARE formulary.
    Linton A; Bacon T; Peterson M
    J Manag Care Pharm; 2009; 15(1):42-54. PubMed ID: 19125549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of therapeutic interchange on medication reconciliation during hospitalization and upon discharge in a geriatric population.
    Wang JS; Fogerty RL; Horwitz LI
    PLoS One; 2017; 12(10):e0186075. PubMed ID: 29049325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of an intervention in an academic Internal Medicine Clinic to continue, step-down, or discontinue proton pump inhibitor therapy related to a tennessee medicaid formulary change.
    Ramser KL; Sprabery LR; Hamann GL; George CM; Will A
    J Manag Care Pharm; 2009 May; 15(4):344-50. PubMed ID: 19422274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formulary management of proton pump inhibitors.
    Byrne MF; Murray FE
    Pharmacoeconomics; 1999 Sep; 16(3):225-46. PubMed ID: 10558037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of a therapeutic maximum allowable cost (MAC) program on the cost and utilization of proton pump inhibitors in an employer-sponsored drug plan in Canada.
    Mabasa VH; Ma J
    J Manag Care Pharm; 2006 Jun; 12(5):371-6. PubMed ID: 16792443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inpatient medication reconciliation at admission and discharge: A retrospective cohort study of age and other risk factors for medication discrepancies.
    Unroe KT; Pfeiffenberger T; Riegelhaupt S; Jastrzembski J; Lokhnygina Y; Colón-Emeric C
    Am J Geriatr Pharmacother; 2010 Apr; 8(2):115-26. PubMed ID: 20439061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential savings of harmonising hospital and community formularies for chronic disease medications initiated in hospital.
    Lapointe-Shaw L; Fischer HD; Newman A; John-Baptiste A; Anderson GM; Rochon PA; Bell CM
    PLoS One; 2012; 7(6):e39737. PubMed ID: 22761882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of nonformulary use of PPIs and excess drug cost in a Veterans Affairs population.
    Ajumobi AB; Vuong R; Ahaneku H
    J Manag Care Pharm; 2012; 18(1):63-7. PubMed ID: 22235956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proton pump inhibitors for acid suppression in the intensive care unit: formulary considerations.
    Devlin JW
    Am J Health Syst Pharm; 2005 May; 62(10 Suppl 2):S24-30. PubMed ID: 15905598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breadth, Depth and Agreement among Provincial Formularies in Canada.
    Morgan S; Hanley G; Raymond C; Blais R
    Healthc Policy; 2009 May; 4(4):e162-84. PubMed ID: 20436800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A therapeutic substitution policy for proton pump inhibitors: clinical and economic consequences.
    Schneeweiss S; Maclure M; Dormuth CR; Glynn RJ; Canning C; Avorn J
    Clin Pharmacol Ther; 2006 Apr; 79(4):379-88. PubMed ID: 16580906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacist and physician satisfaction and rates of switching to preferred medications associated with an instant prior authorization program for proton pump inhibitors in the North Carolina Medicaid program.
    Jacobson Vann JC; Christofferson S; Humble CG; Wegner SE; Feaganes JR; Trygstad TK
    J Manag Care Pharm; 2010 May; 16(4):250-63. PubMed ID: 20433216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapeutic interchange of drugs not included in the hospitaĺs pharmacotherapeutic guide: a quality program].
    Navarro de Lara S; Font Noguera I; Lerma Gaude V; López Briz E; Martínez Pascual MJ; Poveda Andrés JL
    Farm Hosp; 2004; 28(4):266-74. PubMed ID: 15369437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal analysis of the costs associated with inpatient initiation and subsequent outpatient continuation of proton pump inhibitor therapy for stress ulcer prophylaxis in a large managed care organization.
    Thomas L; Culley EJ; Gladowski P; Goff V; Fong J; Marche SM
    J Manag Care Pharm; 2010 Mar; 16(2):122-9. PubMed ID: 20178397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-indication Pharmacotherapeutic Multicriteria Decision Analytic Model for the Comparative Formulary Inclusion of Proton Pump Inhibitors in Qatar.
    Al-Badriyeh D; Alabbadi I; Fahey M; Al-Khal A; Zaidan M
    Clin Ther; 2016 May; 38(5):1158-73. PubMed ID: 27021610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decision support at the point of prescribing to increase formulary adherence.
    Helmons PJ; Coates CR; Kosterink JG; Daniels CE
    Am J Health Syst Pharm; 2015 Mar; 72(5):408-13. PubMed ID: 25694416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of discharge medication orders following automatic therapeutic substitution of commonly exchanged drug classes.
    Glaholt S; Hayes GL; Wisniewski CS
    P T; 2014 Apr; 39(4):267-77. PubMed ID: 24757364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formularies in integrated health systems: Fallon Healthcare System.
    Cano SB
    Am J Health Syst Pharm; 1996 Feb; 53(3):270-3. PubMed ID: 8808021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased health costs from mandated Therapeutic Substitution of proton pump inhibitors in British Columbia.
    Skinner BJ; Gray JR; Attara GP
    Aliment Pharmacol Ther; 2009 Apr; 29(8):882-91. PubMed ID: 19183155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.